New assay could revolutionize detection and treatment of acute myeloid leukemia

A novel assay that detects a unique molecular marker in patients with acute myeloid leukemia (AML) may revolutionize the way this disease is detected and treated according to a new report opens in new tab/window in The Journal of Molecular Diagnostics opens in new tab/window published by Elsevier. This assay may improve detection of AML driven by KMT2A gene fusions and may affect treatment decision-making, assessing response to therapy, and long-term surveillance.

AML is a rare, aggressive blood cancer diagnosed in around 120,000 individuals worldwide each year. Detecting residual disease during treatment is essential for determining prognosis and guiding treatment decisions. Currently, the methods for detecting measurable residual disease (MRD) during treatment for AML include bone marrow morphology, multiparameter flow cytometry (MPFC), and DNA sequencing. Morphologic assessment only detects leukemic cells at a 5% limit of detection. MPFC has a more sensitive limit of detection at 0.01% to 0.001%, but is challenging to implement and interpret, and is not standardized between laboratories. DNA sequencing approaches can identify leukemic cells by their somatic mutation profile but are expensive and can be confounded by clonal hematopoiesis in non-leukemic blood cells.

Lead investigator Grant A. Challen, PhD, Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis. Explains, “Oncogenic fusions are often disease-defining and present a unique marker of leukemic cells that are not usually present in healthy cells. Other diseases such as chronic myeloid leukemia (CML) can already be tracked by the canonical BCR-ABL fusion and sensitively detecting these fusions has revolutionized how CML is treated. For AML patients with oncogenic fusions driving their disease, the KMT2A fusion is a molecular marker that can be leveraged for sensitive MRD detection. We therefore wanted to develop a platform for sensitive KMT2A fusion-detection to improve how we detect and treat this disease.”

Investigators developed a novel droplet digital PCR assay enabling sensitive KMT2A fusion detection with the five most common fusion partners. There are at least 80 known KMT2A fusion partners, but about 80% of fusions involve just five partners — AF9, AF6, AF4, ELL, and ENL. They benchmarked the assay in human cell lines and patient samples to demonstrate sensitive and specific KMT2A fusion detection. The assay detects these fusions by partitioning cDNA molecules into microfluidic droplets that are assayed with primers and probes that only produce a positive signal when fusion transcripts are present. Investigators were able to combine multiple primer/probe sets targeting different fusions into a pooled fusion detection reagent. They also showed detection of KMT2A fusions in patient samples known to harbor KMT2A fusions.

Dr. Challen notes, “We show that the assay does not produce false-positive signals in samples from healthy individuals. The assay is easily expanded to include additional oncogenic fusions. This has potential impact for treatment decision-making and assessing response to therapy. Knowing whether a treatment is working or not is critically important for decisions regarding when to escalate therapy or pursue hematopoietic stem cell transplant.”

He concludes, “This is a robust new tool for sensitive KMT2A fusion detection that is directly applicable for disease detection in patients with leukemia driven by these fusions. It fills a void for oncogenic fusion detection and provides some technical improvements. The assay is also scalable—additional fusions can be easily added to the assay—to expand coverage for other oncogenic fusions. We are improving blood cancer detection one drop at a time!”

---

Notes for editors

The article is “Droplet Digital PCR for Oncogenic KMT2A Fusion Detection,” by Andrew L. Young, Hannah C. Davis, and Grant A. Challen (https://doi.org/10.1016/j.jmoldx.2023.09.006 opens in new tab/window). It appears online ahead of The Journal of Molecular Diagnostics, volume 25, issue 12 (December 2023), published by Elsevier.

The article is openly available at https://www.jmdjournal.org/article/S1525-1578(23)00222-2/fulltext opens in new tab/window.

Full text of this study is also available to credentialed journalists upon request; contact Eileen Leahy at +1 732 238 3628 or [email protected] opens in new tab/window. Journalists wishing to interview the authors should contact Dr. Grant Challen at +1 314 362 0987 or [email protected] opens in new tab/window.

The study was partly supported by NIH grants R01 HL147978, R01 CA236819, and R01 DK124883, the Leukemia and Lymphoma Society, and an ASH Research Training Award for Fellows.

About The Journal of Molecular Diagnostics

The Journal of Molecular Diagnostics opens in new tab/window, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition. www.jmdjournal.org opens in new tab/window

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation opens in new tab/window, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX opens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.